Showing results (151-160 of 190) with videos related to
Sort By:
Pageof 19
Journal of Translational Medicine|November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.European Journal of Cancer (Oxford, England : 1990)|April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 studyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2018
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid TumorsJason J Luke, Jeffrey M Lemons, Theodore G Karrison, et al.The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.Journal of Translational Medicine|July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid TumorsCorey C Foster, Gini F Fleming, Theodore G Karrison, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I TrialJason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.Pageof 19